News & Updates

‘Breakthrough’ treatment slashes coronavirus death risk: UK study


Excerpt from the article: “An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the…

Read More

New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs


Excerpt from the article: “GENEVA and SUNNYVALE, Calif., July 16, 2020 /PRNewswire/ — The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe…

Read More

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients


Excerpt from the press release: MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–Jul. 16, 2020– PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046…

Read More

New Research Finds Asthma Drug Very Promising In Treating Alzheimer’s Disease


Excerpt from the article: “A laboratory study determined that asthma drug salbutamol can help prevent the formation of proteins associated with Alzheimer’s disease. Since this was still a lab study, scientists wanted to take the next step of testing the drug in animal models. Brains of those suffering from Alzheimer’s disease show plaques between the…

Read More

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease


Excerpt from the Press Release: “LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer’s disease.…

Read More

Pear Therapeutics Announces First Participant Enrolled in Virtual Real-World Study of Adults with Chronic Insomnia


Excerpt from the Press Release: “BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc. today announced the first participant enrolled in an open-label, decentralized clinical trial (called the DREAM study) evaluating Somryst™, an FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia. The DREAM study will enroll approximately 350 adults in the United States with…

Read More

Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19


Excerpt from the Press Release: “LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality…

Read More

Connecting donated human lungs to pigs repaired damage to the organs, scientists report


Excerpt from the article: “For people who need a lung transplant, the wait is often prolonged by the frustrating fact that most donor organs have to be discarded: Only 20% of donated lungs meet medical criteria for transplantation, translating into far fewer organs than people on waiting lists. Now, a team of researchers has shown…

Read More

Wyss Institute gets $16M to repurpose FDA-approved drugs for Covid-19


Excerpt from the article: “As the scientific community races toward potential treatments for Covid-19, the respiratory illness caused by the novel coronavirus that has now killed at least 116,000 Americans, researchers at Harvard’s Wyss Institute are partnering with institutions across the U.S. on a new project using old materials. The Wyss Institute has signed a…

Read More

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions


Excerpt from the press release: “SAN FRANCISCO–(BUSINESS WIRE)–IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic.…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?